Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

MicroRNAs as effectors of p53 and BRCA1 in high grade serous ovarian cancer

EF 2018-19

Résumé
Ovarian cancer remains one of the deadliest cancers in spite of growing knowledge on its underlying mechanisms. More than 80% of ovarian cancer deaths are associated with high-grade serous ovarian cancer (HGSOC), a sub-type of the disease that carries alterations in the genes TP53, BRCA1 and BRCA2. TP53 encodes the tumour suppressive (anti-cancer) protein p53, which can become pro-cancer as a consequence of genetic alterations that occur in HGSOC. An important part of the anti-cancer functions of p53 is exerted through a class of short nucleic acids called microRNAs (miRNAs), which exert a widespread control over gene expression, and establish a delicate balance in normal gene functions. Changes in their expression patterns can be used to distinguish types of tumour, reflect the underlying gene defects, and point to sensitivity or resistance to drug treatment. With this project, we will use miRNA profiles to guide our understanding of the genetic defects underlying HGSOC, and determine the interplay of TP53, BRCA1 and miRNAs in response to drug treatments. Towards this, we will develop a panel of HGSOC cell lines bearing very specific genetic lesions in TP53 and BRCA1, using genome edition methods (CRISPR). We will define the impact of these gene defects on miRNA expression with and without treatment with anticancer drugs, and determine their functional importance for treatment sensitivity in HGSOC. This project will provide insight on the synergistic actions of P53 and BRCA1 through miRNAs, and potentially new mechanisms of drug resistance in HGSOC.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
404160
Name
Tseng Hsin Wei
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
MicroRNAs as effectors of p53 and BRCA1 in high grade serous ovarian cancer
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Crispr; Microrna; Ovarian Cancer; Sequencing
Abstract
Ovarian cancer remains one of the deadliest cancers in spite of growing knowledge on its underlying mechanisms. More than 80% of ovarian cancer deaths are associated with high-grade serous ovarian cancer (HGSOC), a sub-type of the disease that carries alterations in the genes TP53, BRCA1 and BRCA2. TP53 encodes the tumour suppressive (anti-cancer) protein p53, which can become pro-cancer as a consequence of genetic alterations that occur in HGSOC. An important part of the anti-cancer functions of p53 is exerted through a class of short nucleic acids called microRNAs (miRNAs), which exert a widespread control over gene expression, and establish a delicate balance in normal gene functions. Changes in their expression patterns can be used to distinguish types of tumour, reflect the underlying gene defects, and point to sensitivity or resistance to drug treatment. With this project, we will use miRNA profiles to guide our understanding of the genetic defects underlying HGSOC, and determine the interplay of TP53, BRCA1 and miRNAs in response to drug treatments. Towards this, we will develop a panel of HGSOC cell lines bearing very specific genetic lesions in TP53 and BRCA1, using genome edition methods (CRISPR). We will define the impact of these gene defects on miRNA expression with and without treatment with anticancer drugs, and determine their functional importance for treatment sensitivity in HGSOC. This project will provide insight on the synergistic actions of P53 and BRCA1 through miRNAs, and potentially new mechanisms of drug resistance in HGSOC.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tseng, Hsin Wei
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~